Lucia Mangone1, Francesca Ferrari2, Pamela Mancuso2, Giuliano Carrozzi3, Maria Michiara4, Fabio Falcini5,6, Silvano Piffer7, Rosa Angela Filiberti8, Adele Caldarella9, Francesco Vitale10, Rosario Tumino11, Angelita Brustolin12, Giovanna Tagliabue13, Paolo Giorgi Rossi2, Laura Ottini14. 1. Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Via Amendola 2, 42122, Reggio Emilia, Italy. mangone.lucia@ausl.re.it. 2. Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Via Amendola 2, 42122, Reggio Emilia, Italy. 3. Epidemiology Unit, Azienda Unità Sanitaria Locale, Via Martiniana 21, 41126, Baggiovara, Modena, Italy. 4. Medical Oncology Unit, University Hospital of Parma, Parma, Italy. 5. Romagna Cancer Registry, Romagna Cancer Institute (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS), Meldola, Forlì, Italy. 6. Azienda Usl della Romagna, Forlì, Italy. 7. Department of Clinical and Evaluative Epidemiology, Trento Health Service, Trento, Italy. 8. Clinical Epidemiology Unit, Ospedale Policlinico San Martino, Genoa, Italy. 9. Tuscany Cancer Registry, Clinical and Descriptive Epidemiology Unit, Cancer Prevention and Research Institute (ISPO), Florence, Italy. 10. Department of Science for Health Promotion and Mother to Child Care "G. D'Alessandro", University of Palermo, Palermo, Italy. 11. Histopathology Department and Cancer Registry, Provincial Health Authority, ASP Ragusa, Piazza Igea 1, 97100, Ragusa, Italy. 12. UOC PreSAL-Dipartimento di Prevenzione ASL Viterbo, c/o Cittadella della Salute, Via E. Fermi, 15, 01100, Viterbo, Italy. 13. Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy. 14. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Abstract
AIM: To evaluate the epidemiology of male breast cancer (MBC) in Italy and to describe incidence and survival data in relation to age, morphology, year of incidence, geographic area, and possible association with other cancers compared with female BC. METHODS: Cases were extracted from 40 Italian Cancer Registries. Standardized incidence rates (SIR), age-specific rates, and 5-year survival were calculated. The association with second tumors was also evaluated. All data were compared with data from female BCs. RESULTS: In the 2000-2014 period, 2175 new cases of MBC were registered, with an SIR of 1.7 × 100,000. The incidence showed a slight upward trend and increased with increasing age. The 5-year survival was 82% in the first two periods (2000-2004, 2005-2009), lower than in females (87%). The most frequent morphology was the ductal carcinoma (84%). Stage at diagnosis was 39.5% stage I, 33.1% stage II, 20.9% in stage III, and 6.4% in stage IV. Concerning receptor status, 96.4% had ER+ and 82.5% PR+; 46.5% had high Ki67 and 14.7% HER2 amplified. The risk of BC increased if the man had already had a previous tumor in any site (excess absolute risk, EAR = 2.7) and especially if he had had prostate cancer (EAR = 5.1). Instead, males with a previous diagnosis of BC had an increased risk of testicular, kidney and lung cancer. CONCLUSIONS: MBC requires more attention in terms of diagnosis and treatment as clinicians tend to follow the guidelines that have been developed for female BC management.
AIM: To evaluate the epidemiology of male breast cancer (MBC) in Italy and to describe incidence and survival data in relation to age, morphology, year of incidence, geographic area, and possible association with other cancers compared with female BC. METHODS: Cases were extracted from 40 Italian Cancer Registries. Standardized incidence rates (SIR), age-specific rates, and 5-year survival were calculated. The association with second tumors was also evaluated. All data were compared with data from female BCs. RESULTS: In the 2000-2014 period, 2175 new cases of MBC were registered, with an SIR of 1.7 × 100,000. The incidence showed a slight upward trend and increased with increasing age. The 5-year survival was 82% in the first two periods (2000-2004, 2005-2009), lower than in females (87%). The most frequent morphology was the ductal carcinoma (84%). Stage at diagnosis was 39.5% stage I, 33.1% stage II, 20.9% in stage III, and 6.4% in stage IV. Concerning receptor status, 96.4% had ER+ and 82.5% PR+; 46.5% had high Ki67 and 14.7% HER2 amplified. The risk of BC increased if the man had already had a previous tumor in any site (excess absolute risk, EAR = 2.7) and especially if he had had prostate cancer (EAR = 5.1). Instead, males with a previous diagnosis of BC had an increased risk of testicular, kidney and lung cancer. CONCLUSIONS:MBC requires more attention in terms of diagnosis and treatment as clinicians tend to follow the guidelines that have been developed for female BC management.
Entities:
Keywords:
Clinical and biological characteristics; Male breast cancer; Second cancers; Stage; Survival
Authors: Roberta Caputo; Alessandra Fabi; Emanuela Romagnoli; Editta Baldini; Donatella Grasso; Nicola Fenderico; Andrea Michelotti Journal: Breast Cancer (Dove Med Press) Date: 2022-10-18
Authors: Ksenija Strojnik; Mateja Krajc; Vita Setrajcic Dragos; Vida Stegel; Srdjan Novakovic; Ana Blatnik Journal: Breast Cancer Res Treat Date: 2021-04-23 Impact factor: 4.872